Jump to contentJump to search

Recent publication in LancetEBioMedicine
Neuroregeneration in multiple sclerosis - new participating cells and supportive drug identified

There is currently no treatment that causes tissue regeneration and functional recovery in the adult central nervous system (CNS), i.e. brain and spinal cord, after injury or disease. Regeneration in the CNS is a rare event and is severely limited to the replacement of so-called oligodendroglial cells and their electrically insulating elements of axons called myelin sheaths. This is also true for Multiple Sclerosis (MS), a disease that affects millions of people worldwide and leads to lifelong and progressive impairment of patients. The research team of Prof. Patrick Küry at the Department of Neurology at the University Hospital Düsseldorf now describes in the journal Lancet EBioMedicine that the corticosteroid medryson is highly effective in promoting the replacement of lost oligodendroglial cells and and also improves the restoration of myelin sheaths hence the electrical isolation of axons.


Yellow marked astrocytes (by means of immunofluorescence labeling) within regenerating mouse brain tissue express a promising protein marker combination (C3d and S100a10) leading to a cellular phenotype fostering myelin repair.

In their latest research article led by first author Markley Silva Oliveira-Junior, a talented PhD student from Brazil working in the Düsseldorf group, the observation in the mouse model that the regeneration effect by Medrysone was is mediated via a completely unexpected cell type - astrocytes - was surprising.

In their study, the scientists were able to show for the first time that astrocytes react specifically in situations where myelin structures are damaged and appear in many different subtypes. Some of these phenotypes attempt to support local tissue repair activities, while others are more oriented toward more severe tissue destruction and even contribute additionally to lesion formation. Highly complex and dynamic behavior was observed, but this in fact be directed by the Medrysone drug toward protective and regenerative cells and toward "taming" neurotoxic astrocyte populations. These findings are unexpected and novel in the field of neuroregeneration in MS. Küry and team have been studying regenerative processes for many years with the goal of identifying new aspects, cell responses, and pharmacological agents to improve regeneration efficiency.

Original publication:

Silva Oliveira-Junior, M., Schira-Heinen, J., Reiche, L., Han, S., de Amorim, V.C.M., Lewen, I., Gruchot, J., Göttle, P., Akkermann, R., Azim, K., and Küry, P. (2022) Myelin repair is fostered by the corticosteroid medrysone specifically acting on astroglial subpopulations. EBioMedicine 83:104204. doi: 10.1016/j.ebiom.2022.104204. (Online ahead of print).

Kategorie/n: Medizinische Fakultät, Schlagzeilen, Pressemeldungen, Auch in Englisch
Responsible for the content: